Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies
International Journal of Psychiatry and Neurology · 2026 · 15 (04) · 160-168
DOI: 10.12677/ijpn.2026.154018 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Psychiatry and Neurology, 2026. Verfasst von 歆睿 张. Die Arbeit nennt 53 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
张, 歆. (2026). Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies. International Journal of Psychiatry and Neurology, 15(04), 160-168. https://doi.org/10.12677/ijpn.2026.154018
Vancouver
张 歆. Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies. International Journal of Psychiatry and Neurology. 2026;15(04):160-168. doi:10.12677/ijpn.2026.154018
BibTeX
@article{2026,
author = {张, 歆睿},
title = {Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies},
journal = {International Journal of Psychiatry and Neurology},
year = {2026},
volume = {15},
number = {04},
pages = {160--168},
doi = {10.12677/ijpn.2026.154018}
}
EUVIMED